Searchable abstracts of presentations at key conferences in endocrinology

ea0047oc8 | Spotlight on Neuroendocrine tumours | Theranostics2016

NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis

Strosberg Jonathan , Wolin E , Chasen B , Kulke M , Bushnell D , Caplin M , Baum R P , Kunz P , Hobday T , Hendifar A , Oberg K , Lopera Sierra M , Kwekkeboom D , Ruszniewski P , Krenning E

Background: Currently, there are limited therapeutic options for patients with advanced midgut neuroendocrine tumors progressing on first-line somatostatin analog therapy.Methods: NETTER-1 is the first phase III, randomized trial evaluating 177Lu-DOTA0-Tyr3-Octreotate (Lutathera®) in patients with progressive, somatostatin receptor positive midgut NETs. 230 patients were randomized to receive Lutathera 7.4...